journal articles
PREPARING FOR THE IMPLEMENTATION OF ANTI-AMYLOID THERAPIES IN EUROPE: ASSESSING REAL-WORLD ELIGIBILITY FOR LECANEMAB AND DONANEMAB IN A SWEDISH MEMORY CLINIC
Anna Rosenberg, Alina Solomon, Alexandre Bonnard, Makrina Daniilidou, Göran Hagman, Anette Hall, Anna Matton, Ulf Öhlund-Wistbacka, Eric Westman, Miia Kivipelto
Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are excluded. Successful implementation in public healthcare hinges on accurate estimates of eligibility rates in settings which will be the first to roll out the treatments (specialized memory clinics with early disease stages). We applied the appropriate use recommendations (AUR) to assess treatment eligibility in a Swedish tertiary memory clinic where Aβ and APOE assessments are routinely performed. Of the full cohort (N = 410), 26 and 25 patients met the AUR criteria for lecanemab and donanemab, respectively (6 %; partial overlap between the groups). After excluding APOE ε4/4 carriers in line with the European guidelines, only 14 and 13 patients remained eligible (3 %). In clinics with younger populations, a significant percentage of potentially eligible patients are likely to have the APOE ε4/4 genotype. These findings are important to inform the implementation of anti-Aβ treatments.
CITATION:
Anna Rosenberg ; Alina Solomon ; Alexandre Bonnard ; Makrina Daniilidou ; Göran Hagman ; Anette Hall ; Anna Matton ; Ulf Öhlund-Wistbacka ; Eric Westman ; Miia Kivipelto (2025): Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. The Journal of Prevention of Alzheimer’s Disease (JPAD). https://doi.org/10.1016/j.tjpad.2025.100476